Exchange Traded Concepts LLC Has $180,000 Stock Holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX)

Exchange Traded Concepts LLC lowered its position in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) by 12.6% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 97,931 shares of the company’s stock after selling 14,089 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Compass Therapeutics were worth $180,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the business. Opaleye Management Inc. bought a new position in Compass Therapeutics during the first quarter worth about $6,277,000. CM Management LLC grew its position in shares of Compass Therapeutics by 148.0% during the 1st quarter. CM Management LLC now owns 310,000 shares of the company’s stock worth $614,000 after purchasing an additional 185,000 shares in the last quarter. Ground Swell Capital LLC bought a new position in shares of Compass Therapeutics during the second quarter worth approximately $124,000. Vanguard Group Inc. raised its position in shares of Compass Therapeutics by 1.7% in the first quarter. Vanguard Group Inc. now owns 4,152,197 shares of the company’s stock valued at $8,221,000 after buying an additional 71,008 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in shares of Compass Therapeutics by 99.7% in the second quarter. Renaissance Technologies LLC now owns 140,600 shares of the company’s stock valued at $141,000 after buying an additional 70,200 shares during the period. Institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Stock Down 0.5 %

Compass Therapeutics stock opened at $1.85 on Tuesday. The business’s 50-day moving average price is $1.60 and its two-hundred day moving average price is $1.39. Compass Therapeutics, Inc. has a 12-month low of $0.77 and a 12-month high of $2.34. The stock has a market cap of $254.54 million, a PE ratio of -5.14 and a beta of 0.90.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.10). The company had revenue of $0.85 million for the quarter. As a group, analysts expect that Compass Therapeutics, Inc. will post -0.42 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. LADENBURG THALM/SH SH upgraded Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price objective on the stock in a research note on Monday, September 16th. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Compass Therapeutics in a research report on Monday, August 12th. Finally, Wedbush reaffirmed an “outperform” rating and set a $8.00 price objective on shares of Compass Therapeutics in a research report on Wednesday, August 7th.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.